Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
freeze-dried habu antivenom, equine
- Development stage
- Unknown
- Lead developer
- KM Biologics
- Modality
- Antibody-Based Therapeutics
- Administration
- Intramuscular, Intravenous, Subcutaneous
01
Overview
Habu antivenom is an equine-derived, freeze-dried antivenom used for the treatment of envenomation caused by the Habu snake (*Protobothrops flavoviridis*), a highly venomous pit viper native to the Ryukyu Islands of Japan (including Okinawa and Kagoshima). Originally developed by The Chemo-Sero-Therapeutic Research Institute (Kaketsuken) and currently manufactured and developed by KM Biologics, the antivenom is produced by purifying immunoglobulins from the serum of horses immunized with Habu venom or toxoid. It is highly stable in its lyophilized form and is reconstituted with sterile water before administration. The antivenom works by binding to and neutralizing the lethal and hemorrhagic toxins present in Habu venom, preventing systemic toxicity and local tissue damage.
- Brand names
- Freeze-dried Habu Antivenom “KMB”Freeze-dried Habu Equine Antivenom Injection 6000 units “KMB”Habu Antivenom “Kaketsuken”
- Other names
- Freeze-dried Habu Antivenom, EquineHabu antivenomHabu snake antivenom乾燥はぶウマ抗毒素
02
Targets
svPLA2 (Snake venom phospholipase A2)SVMP (Snake venom metalloproteinase)
Beyond the preview
Go deeper on freeze-dried habu antivenom, equine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on freeze-dried habu antivenom, equine.